Latest Breaking News On - Sarepta therapeutics - Page 7 : comparemela.com

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target lifted by Mizuho from $145.00 to $179.00 in a research report sent to investors on Friday morning, Benzinga reports. Mizuho currently has a buy rating on the biotechnology company’s stock. SRPT has been the topic of several other research reports. UBS Group raised their price […]

New jerseyUnited statesStephen mayoRoyal bankSarepta therapeutics company profileSarepta therapeutics incSecurities exchange commissionVanguard group incInvestment managementCapula management ltdJersey common pension fundSarepta therapeuticsFree reportModerate buyGet free reportDirector stephen mayo